STOCKHOLDERS' EQUITY - Stock grant agreements with non-employees (Details)	1 Months Ended			3 Months Ended	9 Months Ended	30 Months Ended
	Jul. 31, 2022 USD ($) individual shares	Jul. 31, 2020 USD ($) individual	Apr. 30, 2020 USD ($) individual shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 USD ($) individual	Sep. 30, 2022 USD ($)
Share-Based Compensation Awards
Treasury shares at acquisition cost (in dollars)	$ 963,000
Retirement of treasury shares, Reduction in outstanding stock and reduction of APIC (in dollars)				$ 963,000	$ 963,000
Researchers, Employees of MSK
Share-Based Compensation Awards
Number of individuals that repaid note | individual	1
SADA License Agreement | Researchers, Employees of MSK
Share-Based Compensation Awards
Number of individuals | individual		2
Notes receivable, noncurrent		$ 2,610,000
Notes receivable term		3 years
Notes receivable interest rate (as a percent)		1.00%
SADA License Agreement | Nonemployees | Researchers, Employees of MSK
Share-Based Compensation Awards
Number of individuals | individual			2		2
Vesting (as a percent)			40.00%		20.00%	80.00%
Remaining vesting percentage			60.00%	20.00%	20.00%	20.00%
SADA License Agreement | Nonemployees | Researchers, Employees of MSK | Research and development expense
Share-Based Compensation Awards
Non-cash expense in connection with equity issuance to non-employees			$ 7,376,000
Unrecognized compensation				$ 0	$ 0	$ 0
SADA License Agreement | Nonemployees | Researchers, Employees of MSK | Tranche two
Share-Based Compensation Awards
Vesting period			3 years
Common Stock
Share-Based Compensation Awards
Number of shares exchanged | shares	57,887			57,887
Common Stock | SADA License Agreement | Nonemployees | Researchers, Employees of MSK
Share-Based Compensation Awards
Shares agreed to be issued | shares			213,996
Issuance of common stock to non-employees (in shares) | shares			213,996